# Real world tirzepatide treatment for fatty liver disease.

> PubMed lists PMID 41776028 in Hepatology international as Editorial, with publication-date metadata of 2026-03-03 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41776028-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-04-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41776028-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41776028-tirzepatide-v1.json
- Content SHA-256: `e0845d2126315ff2ab5068d218888095662cd96d74e76aadde57e7dda89ea3aa`

## Claims and source pins

### Headline

Real world tirzepatide treatment for fatty liver disease. ([`pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531`](#source-pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531))

### Summary

PubMed lists PMID 41776028 in Hepatology international as Editorial, with publication-date metadata of 2026-03-03 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531`](#source-pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531))

### Paragraph 1

PubMed lists PMID 41776028 in Hepatology international as Editorial, with publication-date metadata of 2026-03-03 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531`](#source-pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531`](#source-pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531))

## Sources

<a id="source-pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531"></a>
- **Real world tirzepatide treatment for fatty liver disease. · retained source version 1:2026-04-27:current:3b5833d9453153cb871b177a7dbed1e756c477207b8a301d62526b955ba80697** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41776028/) (`pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Real world tirzepatide treatment for fatty liver disease." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41776028-tirzepatide-v1.json SHA-256: e0845d2126315ff2ab5068d218888095662cd96d74e76aadde57e7dda89ea3aa.